CADTH Evidence Helps Alberta Update Coverage of Proton Pump Inhibitors

Earlier this month, Alberta Health used evidence produced by CADTH to help inform changes in how it covers proton pump inhibitors (PPIs) — a type of medication used to treat stomach and digestive problems.

Our detailed review of PPIs showed that all medications for acid reflux conditions, both brand-name and generic versions, are considered therapeutically similar and equally effective.

Effective February 2017, Alberta Health will cover only the lowest-cost PPIs. Patients who switch to the lower-cost medications will have a lower co-payment and save on out-of-pocket costs, with no impact on their health outcomes.

“At CADTH, we believe that credible, objective evidence should inform every important health care decision. Our research shows that all PPIs at equivalent doses work equally well for the treatment of acid-related gastrointestinal conditions. We’re pleased that our research is helping to inform Canada’s policy decisions and contributing to the sustainability of our health care system.”

- Brent Fraser, Vice-President of Pharmaceutical Reviews